Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

A team from Precisa Medicamentos has visited the Bharat Biotech facility last week to discuss potential export possibilities of COVAXIN™, India’s first indigenous vaccine for COVID-19. The team met Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech on the January 7-8 at the Bharat Biotech facility in Genome Valley, Hyderabad. During the discussion, André Aranha Corrêa do Lago, Ambassador of Brazil to India, joined on a virtual platform. He expressed his keen interest on behalf of the Govt of Brazil, towards the procurement of COVAXIN™. In principle, it is understood between both parties that supplies of COVAXIN™ to be prioritised for the public market, through a direct procurement by the Govt of Brazil. Supplies to the private market would be based upon receipt of market authorisation from ANVISA, the Brazilian regulatory authority.

Pleased with the interest expressed by the Brazilian government, Dr Ella said COVAXIN™ is an innovation and a perfect example of novel product development from India. Our goal for all vaccines developed at Bharat Biotech is to provide global access to populations that need it the most. COVAXIN™ has generated excellent safety data with robust immune responses to multiple viral proteins that persist. We are happy to note that vaccines innovated in India are able to address the public health needs of Brazil. ”

After the technical visit to Bharat Biotech's Genome Valley facility in Hyderabad, Emanuela Medrades, Pharmaceutical Director, Precisa Medicamentos, said “Bharat Biotech has exceeded our expectations, demonstrating quality and safety at the level of the largest vaccine suppliers in the world.”